Risk factors of post‐operative recurrence and adequate surgical approach to improve long‐term outcomes of hepatocellular carcinoma-Reference-Cited by-同舟云学术

Risk factors of post‐operative recurrence and adequate surgical approach to improve long‐term outcomes of hepatocellular carcinoma

Published:2013-01 Issue:1 Volume:15 Page:31-39
ISSN:1365-182X
Container-title:HPB
language:en
Short-container-title:HPB

Author:

Shindoh Junichi,Hasegawa Kiyoshi,Inoue Yosuke,Ishizawa Takeaki,Nagata Rihito,Aoki Taku,Sakamoto Yoshihiro,Sugawara Yasuhiko,Makuuchi Masatoshi,Kokudo Norihiro

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference35 articles.

1. Hepatocellular carcinoma: current management and perspectives for the future;Rahbari;Ann Surg,2011

2. Intrahepatic recurrence after resection of hepatocellular carcinoma complicating cirrhosis;Belghiti;Ann Surg,1991

3. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value;Grazi;Ann Surg,2001

4. Prognostic significance of anatomical resection and des‐gamma‐carboxy prothrombin in patients with hepatocellular carcinoma;Imamura;Br J Surg,1999

5. Repeat hepatic resection for recurrent hepatocellular carcinoma;Kakazu;Hepatogastroenterology,1993

Cited by 107 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic Variants in p53 Pathway Genes Affect Survival of Patients with HBV-Related Hepatocellular Carcinoma;Journal of Hepatocellular Carcinoma;2024-08

2. Genetic variants of m⁶A modification genes are associated with survival of HBV‐related hepatocellular carcinoma;Journal of Cellular and Molecular Medicine;2024-08

3. Novel genetic variants in the NLRP3 inflammasome-related PANX1 and APP genes predict survival of patients with hepatitis B virus-related hepatocellular carcinoma;Clinical and Translational Oncology;2024-08-01

4. Exosomal mRNA in plasma serves as a predictive marker for microvascular invasion in hepatocellular carcinoma;Journal of Gastroenterology and Hepatology;2024-07-07

5. Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial;Nature Communications;2024-04-16